Persistence of oral anticoagulant treatment for atrial fibrillation in the Netherlands: A surveillance study

• DOI: 10.1002/rth2.12261
• Publication Date: 2019-10-25T06:14:32Z
• Authors: Gilda Denise Ziel...; Nienke van Rein; Martina Teichert; Frederikus A. Klok; Frits R. Rosendaal; Felix J.M. van de...; Menno V. Huisman; Suzanne C. Canneg...; Willem M. Lijfering
• Keywords: Persistence (discontinuity); Vitamin K antagonist; Oral anticoagulant; Cumulative incidence; Concomitant

In contrast to vitamin K antagonists (VKA), direct oral anticoagulants (DOAC's) are not strictly monitored and dose titrated by anticoagulation clinics in the Netherlands. This may affect drug persistence of atrial fibrillation (AF) patients, whom often require lifelong treatment.